Success Stories: From Global Recognition to National Impact: EB1A Approval Secured for Leading Immunologist

Client’s Testimonial:

“Thank you so much for all your help. My attorney was amazing with his suggestions on improving the layout and how to present the case. Absolutely the best in the business. Happy to write a review after all this! This indeed was a long journey- but I do see the light at the end of the tunnel now.”

On July 23^rd, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Principal in the Field of Immunology (Approval Notice).

General Field: Immunology

Position at the Time of Case Filing: Principal

Country of Origin: India

State of Residence at the Time of Filing: California

Approval Notice Date: July 23^rd, 2025

Processing Time: 4 months, 3 days (Premium Processing Requested)

Case Summary:

Navigating the rigorous demands of an EB1A (Alien of Extraordinary Ability) petition, our client, a highly accomplished immunologist originally from India, has secured approval for permanent residency in the United States. At the time of filing, he was serving as a principal in a scientific management role, contributing to the advancement of immunology and related health sciences through both research and leadership in due diligence for life science innovations.

Trailblazing Research in Immunology

The client’s research centers on molecular mechanisms in immune cells, particularly within the domains of oncology and infectious diseases. His investigations into the stress signaling pathway have opened new avenues in immune-based cancer therapies and treatment strategies for fungal infections. This research is not only pioneering in scope but also directly relevant to urgent public health issues, including the ongoing immunopathology challenges.

Proven Record of Influence

With 5 peer-reviewed journal articles, including first-authored publications in prestigious venues such as Nature, Cell, and Science, the client’s scholarly output has garnered substantial international attention. His work has amassed 1,359 citations and has been utilized by researchers from over 50 countries. Moreover, he has completed at least 13 peer reviews for leading journals and holds an editorial board position at a prestigious immunology journal, underscoring his status as a recognized authority in his field.

Strategic Positioning for U.S. Benefit

Our legal team at NAILG effectively demonstrated how the client satisfies three key EB1A criteria: original contributions of major significance, scholarly authorship, and judging the work of others. We also established through a strong final merits argument that his work directly aligns with U.S. national interests, especially in light of some recent legislative efforts. The client’s research—already funded by institutions such as the NIH and DOD—provides tools for advancing healthcare delivery, reducing opioid reliance, and creating cost-effective solutions for cancer and infectious disease treatment.

EB1A Approval and Outlook

With the petition filed on March 20, 2025, and approved swiftly by July 23, 2025, this success marks another milestone for our team at North America Immigration Law Group (NAILG) in advocating for scientists whose innovations serve both national and global health priorities. We are honored to have supported this immunologist in continuing his groundbreaking work in the United States, where his future contributions will undoubtedly enhance public health outcomes and scientific progress.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.